<DOC>
	<DOCNO>NCT00002465</DOCNO>
	<brief_summary>RATIONALE : Some hormone stimulate growth type cancer cell . Hormone therapy use megestrol may fight cancer reduce production hormone . PURPOSE : Phase I/II trial study effectiveness high-dose megestrol treat patient metastatic breast cancer , endometrial cancer , mesothelioma treat surgery radiation therapy .</brief_summary>
	<brief_title>High-Dose Megestrol Treating Patients With Metastatic Breast Cancer , Endometrial Cancer , Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate clinical effect high-dose oral megestrol improve regression rate prolong survival patient breast endometrial carcinoma mesothelioma . II . Evaluate immune , endocrine , clinical effect regimen , particular attention effect cachexia . OUTLINE : This randomize study . Patients stratify performance status , dominant site disease , prior treatment megestrol . Breast cancer patient randomize one 3 dose oral megestrol ( 800 , 1,280 , 1,600 mg/day , divide qid ) . Female patient tumor type nonrandomly assign receive oral megestrol 1,600 mg/day . Male patient nonrandomly assign dose-finding study megestrol . The first patient cohort receive megestrol 480 mg/day 3 divided dos , escalation subsequent cohort tolerate . All patient continue therapy least 8 week , treatment discontinue upon progression . Measurable lesion evaluate every 2 month . PROJECTED ACCRUAL : 9 evaluable breast cancer patient dose level enter ; 14 patient required disease category . ( As 11/92 , study temporarily close patient prostate cancer . )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document metastatic breast endometrial carcinoma mesothelioma amenable surgical and/or radiotherapeutic cure longterm control Measurable soft tissue , bony , visceral lesion require Indicator lesion blastic bony metastases pleural effusion require breast cancer Hormone receptor status ( breast cancer ) : Estrogenreceptorpositive and/or progesteronereceptorpositive PATIENT CHARACTERISTICS : Age : At least 18 Sex ( breast cancer ) : Not specify Menopausal status ( breast cancer ) : Any status Performance status : Not specify Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since therapy Chemotherapy : At least 4 week since therapy Endocrine therapy : Breast cancer : At least disease stabilization achieve follow tamoxifen hormonal manipulation treatment give previously At least 4 week since therapy Nonbreast cancer patient may enter immediately conventional dos megestrol hormone Radiotherapy : At least 4 week since therapy Concomitant radiotherapy nonindicator lesion allow Surgery : At least 4 week since therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>